Ipca Laboratories has launched Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

Diulcus will be made available to the patients of DFU by Ipca Laboratories through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.